STAT+: Pharmalittle: Two key FDA officials leaving amid Covid-19 booster debate; is Biden really ‘following the science’?
Hello, everyone, and welcome to the middle of the week. You made it this far,…
Category: Pharmalot
STAT+: Pharmalittle: BIO wrestles with inner turmoil; J&J HIV vaccine failed to prevent infection
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT+: ‘A step in the right direction for national security’: An antibiotic plant reopens in Tennessee to make penicillin
Amid a push to bolster antibiotic manufacturing in the U.S., a facility that closed last…
STAT+: Pharmalittle: Contaminants found in Moderna Covid-19 vaccine in Japan; demand rises for ivermectin to treat the coronavirus
Good morning, everyone, and nice to see you again. We have returned from a week-long…
.jpg)
STAT+: Pharmalittle: Judge delays ruling on Purdue opioid settlement; Biomarin dwarfism drug cleared in Europe
Good day, everyone! Nick Florko here filling in for the great Ed Silverman. I’m here…
.jpg)
STAT+: Pharmalittle: Judge plans to rule on Purdue settlement Friday; Biden administration considering Covid boosters after six months
Good morning, fellow humans. Erin Brodwin here, filling in for Ed Silverman. My unofficial mascot,…
STAT+: Pharmalittle: Second J&J vaccine dose boosts antibodies against Covid; age lowered for diabetes screening
Good morning! Katie Palmer here, tagging in for Ed Silverman as he embraces the final…
Pharmalittle: New wave of employer Covid-vaccine mandates expected; drug makers and FDA agree on new programs for rare-disease drugs
Good morning! This is Lev Facher, subbing today for Ed Silverman. I’d be remiss not…
STAT+: Pharmalittle: Pfizer to buy Trillium in $2.3 billion deal; Israel data find additional vaccine dose lowers Covid risk
Good morning everyone, hope you’re savoring the fresh start that comes with the beginning of…
STAT+: Pharmalittle: Biden reportedly rules out Woodcock as FDA commish; J&J’s Gorsky is stepping aside as CEO
And so, another working week will soon draw to a close. Not a moment too…
STAT+: After company protest, FDA agrees to review controversial drug to prevent premature birth
In an unexpected turn of events, the Food and Drug Administration will hold a hearing…
STAT+: Medical journal editorial writers have financial conflicts of interest, too
In the latest look at conflicts of interest in science, a new analysis found 15%…
STAT+: Pharmalittle: FDA advisory panel members want negative votes to matter more; Illumina closes Grail deal despite regulatory hurdles
Good morning, folks. How are you today? Once again, sunny skies and a cool breeze…
STAT+: WHO urges Roche to ensure equitable access of Covid-19 treatment amid global shortage
The World Health Organization and Unitaid called on Roche (RHHBY) to ensure that existing doses…
STAT+: Pharmalittle: Sesen Bio drug trial marked by misconduct; a Sackler threatens opioid settlement if immunity not granted
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT+: David Sackler acknowledges ‘moral responsibility’ to address opioid crisis, but refuses to pay settlement without immunity
Amid a contentious bankruptcy court trial, a member of the Sackler family that owns Purdue…
STAT+: As use of widely prescribed stimulants increases, experts see troubling parallels to opioid crisis
A new study found that the number of adults who used two widely prescribed stimulants…
STAT+: Former Medivation exec charged with insider trading after buying stock ‘within minutes’ of learning of a deal
Just days before Pfizer (PFE) announced plans to acquire Medivation six years ago, the former…
STAT+: Pharmalittle: Roche reports Actemra shortages due to Delta variant; J&J exports Covid-19 shots made in Africa to Europe
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Pharmalittle: Merck is latest drug maker to end 340B discounts; ‘fractionation’ is promoted to stretch Covid-19 vaccines
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pfizer says ‘trust us’ when it comes to a Covid-19 booster; FDA OKs extra dose of the mRNA shots for some people
And so, another working week will soon come to an end. Not a moment too…
STAT+: As Bluebird backpedals from Europe, small gene and cell therapy players face tough hurdles
After Bluebird Bio (BLUE) announced plans this week to end commercial operations in Europe, the…
STAT+: Pharmalittle: Biden pushes Congress to let Medicare negotiate drug prices; National Academies failed to disclose pharma-friendly committee ties
Rise and shine, another busy day is on the way. And it will be steamy…
STAT+: Veterans Affairs declines to cover Biogen Alzheimer’s drug over effectiveness and safety concerns
The Department of Veterans Affairs has decided not to cover a new Alzheimer’s drug from…
STAT+: Pharmalittle: WHO to lead trial testing three drugs as Covid-19 salves; patient access to antibiotics lacking in wealthy countries
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: ‘Things are so messed up’: Patient access to antibiotics is lacking even in the wealthiest countries
Although 18 innovative antibiotics were approved by regulators in the wealthiest nations over the past…
STAT+: Pharmalittle: Bluebird to wind down European operations over pricing; whither the FDA’s accelerated approval pathway?
Good morning, everyone, and how are you today? The sun is trying to peek through…
STAT+: After leaving patients in limbo, Pfizer agrees to sell a discontinued glaucoma drug
After months of controversy, Pfizer (PFE) has reached a deal to sell a decades-old eye…
STAT+: Pharmalittle: Still no word from Biden on a new FDA chief; CMS pulls ‘most favored nation’ rule for lowering drug prices
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: As White House mulls FDA commissioner job, a sign of industry backing for Woodcock surfaces
Shortly after the Biden administration took office, a letter-writing campaign erupted over who should be…
STAT+: Pharmalittle: FDA expects to have Covid booster plan by early September; feds halt Novavax vaccine funding
Wakey-wakey, everyone. It’s Friday! You can sip your cup of stimulation with satisfaction this morning:…
STAT+: A federal appeals court throws into question the fate of ‘skinny labels’ — and access to generic drugs
In a decision with enormous implications for the U.S. health care system, a federal appeals…
STAT+: U.K. antitrust watchdog issues a provisional ruling that Pfizer engaged in price gouging
After being forced to reassess its original findings, a U.K. antitrust watchdog has issued a…
STAT+: Pharmalittle: HHS watchdog to review FDA approval of Alzheimer’s drug; Moderna sold $4.2 billion of its Covid-19 vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Bayer inks a $1.5 billion deal for a biotech with a proprietary drug discovery platform
In a bid to quickly broaden its drug discovery abilities, Bayer (BAYRY) has reached a…
STAT+: Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug
The federal watchdog at the Department of Health and Human Services will review the process…
STAT+: Canadian agency loses a battle in effort to force a drug maker to lower ‘excessive’ pricing
In a withering ruling, a Canadian appeals court overturned a controversial decision issued four years…
STAT+: Pharmalittle: FDA aims to fully approve Pfizer Covid-19 vaccine by Labor Day; SoftBank grabs $5 billion stake in Roche
Rise and shine, everyone, the middle of the week is already here. Congratulations on making…
STAT+: FDA to importer: keep your active pharma ingredients away from weed killer and antifreeze
What do weed killer, engine antifreeze coolant, dry wall repair products, and active pharmaceutical ingredients…
STAT+: Pharmalittle: Sanofi to pay $3.2 billion to buy Translate Bio; COVAX struggles with Covid-19 vaccine distribution
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: ‘Deeply disappointed’: FTC pulls pay-to-delay case after losing authority to force drug makers to relinquish profits
The Federal Trade Commission has reluctantly withdrawn a remaining claim in a lawsuit over a…
STAT+: Pharmalittle: Pfizer and Moderna raise Covid-19 vaccine prices for Europe; FDA to speed full approval of Pfizer shot
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Pharmalittle: Remdesivir props up Gilead’s declining fortunes; U.K. fines drug maker for price hikes
Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the…
STAT+: FDA threatens to fine another drug maker for failing to report clinical trial results
For only the second time, the Food and Drug Administration is threatening to fine a…
STAT+: Pharmalittle: Emergent to resume Covid-19 vaccine production; FDA OKs first interchangeable biosimilar insulin
Hello, everyone, and how are you today? We are just fine, thank you, despite gray…
STAT+: FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?
In a long-awaited move, the Food and Drug Administration has approved the first so-called interchangeable…
STAT+: Lawmakers ask Defense Department about using a controversial maneuver to lower drug prices
Three years ago, Congress directed the Department of Defense to take steps to lower the…
STAT+: Pharmalittle: Biogen yanks Alzheimer’s paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales
Top of the morning to you, and a fine one, it is. Delicious cool breezes…
STAT+: Animal rights activists get new ammunition in their battle over a controversial rodent test
In what animal rights activists see as a significant development, a pair of U.K. health…
STAT+: Pharmalittle: Pharma lobbies Congress on global tax proposal; the FDA doc at center of Aduhelm controversy
Rise and shine, everyone, another busy day is on the way. We can tell because…